252 related articles for article (PubMed ID: 24627094)
1. Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Kim JE; Lee JI; Jin DH; Lee WJ; Park GB; Kim S; Kim YS; Wu TC; Hur DY; Kim D
Oncol Rep; 2014 May; 31(5):2429-37. PubMed ID: 24627094
[TBL] [Abstract][Full Text] [Related]
2. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
5. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.
Ding H; Han C; Guo D; Wang D; Duan W; Chen CS; D'Ambrosio SM
Int J Cancer; 2008 Dec; 123(12):2931-8. PubMed ID: 18798266
[TBL] [Abstract][Full Text] [Related]
8. [Effect of COX-2 inhibitor celecoxib on proliferation, apoptosis of HL-60 cells and its mechanism].
Xie X; Li J; Wang RC; Geng RL; Wang SY; Wang C; Zhao XY; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):707-11. PubMed ID: 24989281
[TBL] [Abstract][Full Text] [Related]
9. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
10. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.
Chiang WC; Teng CM; Lin SL; Chen YM; Tsai TJ; Hsieh BS
Eur J Pharmacol; 2005 Jul; 517(1-2):1-10. PubMed ID: 15950964
[TBL] [Abstract][Full Text] [Related]
11. Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
Park GB; Choi Y; Kim YS; Lee HK; Kim D; Hur DY
Cancer Lett; 2014 Aug; 350(1-2):5-14. PubMed ID: 24784886
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.
Liu B; Wen JK; Li BH; Fang XM; Wang JJ; Zhang YP; Shi CJ; Zhang DQ; Han M
Cell Death Dis; 2011 Jul; 2(7):e185. PubMed ID: 21796157
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
14. Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells.
Chen Y; Tsai YH; Tseng SH
Anticancer Res; 2011 Jun; 31(6):2231-9. PubMed ID: 21737646
[TBL] [Abstract][Full Text] [Related]
15. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
[TBL] [Abstract][Full Text] [Related]
16. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells.
Roy M; Mukherjee S
Asian Pac J Cancer Prev; 2014; 15(3):1403-10. PubMed ID: 24606473
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
